Dementia and Alzheimer Disease

The investigational Alzheimer disease treatment from Biogen will be re-administered to patients who were previously enrolled in aducanumab trials as they prepare to submit for FDA approval.

The drug proved effective in extending total sleep time over a 4-week study period, with minimal adverse events observed.

The vice president and chief medical officer of the Neurology Business Group at Eisai discussed the company's decision to continue efforts on amyloid therapy despite prior setbacks.

Catch up on some of our most popular video interviews with leaders in the field, including discussions with Imad Najm, MD, James Leverenz, MD, Richard Isaacson, MD, and more.

Neurology News Network for the week ending December 21, 2019.

Compared to counterparts who did not exercise, those with cognitive impairments with no dementia risk factors improved in executive functioning when they exercised consistently over 6 months.

Although there are gaps in knowledge, investigators see potential in telemedicine for other neurologic disorders beyond stroke.

The data presentation from the phase 3 EMERGE and ENGAGE clinical trials suggest that aducanumab may result in disease-modifying effects, slowing clinical decline in those with early Alzheimer disease. Biogen expects to submit a BLA to the FDA for approval in early 2020.

The director emeritus of the Cleveland Clinic Lou Ruvo Center for Brain Health discussed the significance of the HARMONY study findings and what they mean for the future treatment of dementia-related psychosis.

The phase 1/2 trial seeks to will assess the safety and efficacy of mesenchymal stem cells for the treatment of Alzheimer disease.

James Leverenz, MD, director of the Lou Ruvo Center for Brain Health at Cleveland Clinic, sat down to discuss the challenges faced in diagnosing Lewy body dementia.

A study comparing 2 doses of minocycline falls short as the drug failed to slow progression of cognitive or functional decline in people with AD.

Neurology News Network for the week ending November 16, 2019.

Alireza Atri, MD, PhD, medical director of the Banner Sun Health Research Institute, spoke about the importance of open-ended cognitive screening, and the value that early detection and intervention can bring to the table.

The associate professor at Leiden University Medical Center detailed how palliative care can be used more effectively in patients with dementia.

EIP Pharma also announced results from the REVERSE-SD study that examined neflamapimod in early stage Alzheimer disease.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic offered insight into the challenges that have plagued physicians in identifying biomarkers for Lewy body dementia.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed the available options for Parkinson dementia and how they compare in Alzheimer, as well as the ongoing development in Alzheimer.

The Green Valley agent, which is derived from seaweed, showed significant improvements in ADAS-Cog scores over placebo and is anticipated to make its debut on the market in China in late 2019.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed the ground that has been made in treating dementia, and how nuance in diagnosis can provide a possible leg up for physicians.

Neurology News Network for the week ending October 28, 2019.

The chief medical executive at The University of Texas MD Anderson Cancer Center is expected to be named the next commissioner of the FDA by President Donald Trump.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed the diagnostic differences between Lewy body dementia, Alzheimer disease, and other dementias, as well as the importance of proper identification.

The breakthrough study is a concrete example of the opportunities that precision medicine present in the pursuit to prevent the onset of or worsening of diseases like Alzheimer dementia.

Bogged down by a decades-long chase for a common pathology, investigators exploring alternative and complimentary theories are pushing to extend their time in the spotlight.

Study results suggest that adherence to individually tailored interventions, including behavioral, dietary, pharmacologic, educational, and other recommendations can have a positive impact on cognition and reduce risk in patients across the clinical spectrum who have a family history of Alzheimer disease.

Reisa Sperling, MD sat down with NeurologyLive to discuss why she thinks investigational drugs for Alzheimer disease are failing, and what she feels are the most promising treatment avenues.

Neurology News Network for the week ending October 26, 2019.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic laid out these challenges that he and his colleagues face in differentiating patients with Lewy body dementia from other dementia pathologies.

The agency sent a joint letter with the FTC to Rooted Apothecary LLC for claiming its CBD products can medically treat a number of conditions including Alzheimer disease and Parkinson disease. Since 2017, the FDA has issued more than 10 such letters.